Switzerland is missing a potential opening to de-escalate trade friction with the United States by hesitating to streamline the approval process for American medical technology.
With the US set to overhaul its tariff regime on July 24, Bern could have offered rapid regulatory concessions to Washington, but internal resistance within the federal administration is slowing progress.
The hesitation comes as Swiss businesses continue to operate under significant legal and policy uncertainty regarding US trade barriers.
Despite a Supreme Court ruling declaring certain tariffs unlawful, the US government continues to collect them, leaving Swiss exporters exposed to ongoing costs and compliance risks.
This regulatory standoff adds to a broader pattern of stalled diplomacy.
Federal President Guy Parmelin recently confirmed that high-level talks in Washington failed to produce a breakthrough, signaling that the two nations remain at an impasse on key trade issues.